Horby PW, Wei Shen L, Emberson J, Mafham M, Bell J, Linsell L, Staplin N, Brightling C, Ustianowski A, Elmahi W, Prudon B, Green CA, Felton T, Chadwick D, Rege K, Fegan C, Chappell L, Fuast SN, Jaki T, Jeffry K, Montgomery A, Rowan K, Juszczak E, Baillie JK, Haynes R, Landray MJ. Effect of dexamethasone in hospitalised patients with Covid19 - preliminary report. New England Journal of Medicine. July 17 2020.
Docherty AB, Harrison EM, Green CA, Hardwick H, Pius R, Norman L, Holden KA, Read JM, Dondelinger F, Carson G, Merson L, Lee J, Plotkin D, Sigfrid L, Halpin S, Jackson C, Gamble C, Horby PW, Nguyen-Van-Tam JS, Ho A, Russel CD, Dunnng J, Openshaw PJM, Baillie JK, Semple MG. Features of 20 133 UK patients in hospital with Covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. British Medical Journal. 2020;369:m1985. 2020 May 22.
Moran E, Robinson E, Green CA, Keeling M, Collyer B. Towards personalised guidelines: using machine-learning algorithms to guide antimicrobial selection. Journal of Antimicrobial Chemotherapy. 2020 June 15.
Green CA, Sande CJ, Scarselli E, Capone S, Vitelli A, Nicosia A, Silva-Reyes L, Thompson AJ, de Lara CM, Taylor KS, Haworth K, Hutchings CL, Cargill T, Angus B, Klenerman P, Pollard AJ. Novel genetically-modified chimpanzee adenovirus and MVA-vectored respiratory syncytial virus vaccine safely boosts humoral and cellular immunity in healthy older adults. Journal of infection. 2019;78(5):382-392.
Sande CJ, Njunge JM, Mwongeli J, Mutunga MN, Chege T, Gicheru E, Gardiner E, Gwela A, Green CA, Drysdale SB, Berkley JA, Nokes DJ, Pollard AJ. Airway response to respiratory syncytial virus has incidental antibacterial effects. Nature Communications. 2019 May 17; 10 (1):2218
Green CA, Sande CJ, de Lara C, Thompson AJ, Silva-Reyes L, Napolitano F, Pierantoni A, Capone S, Vitelli A, Klenerman P, Pollard AJ. Humoral and cellular immunity to RSV in infants, children and adults. Vaccine. 2018 Aug 31.
Gerretsen HE, Vitelli A, Capone S, Silva-Reyes L, Thompson AJ, Jones CJ, Green CA, Pollard AJ, Sande CJ. Antibodies in lymphocyte supernatants can distinguish between neutralising antibodies incuded by RSV vaccination and pre-existing antibodies induced by natural infection. Vaccine. 2018 Oct 11.
Green CA, Yeates D, Goldacre A, Sande C, Parslow RC, McShane P, Pollard AJ, Goldacre MJ. Admission to hospital for bronchiolitis in England: trends over five decades, geographical variation and association with perinatal characteristics and subsequent asthma. Archives of Diseases in Childhood. 2016 Feb; 101(2):140-6.
Darton TC, Jones C, Blohmke CJ, Wadington CS, Zhou L, Peters A, Haworth K, Sie R, Green CA, Jepperson CA, Moore M, Thompson BA, John T, Kingsley RA, Yu LM, Voysey M, Hindle Z, Lockhart S, Sztein MB, Dougan G, Angus B, Levine MM, Pollard AJ. Using a Human Challenge Model of Infection to Measure Vaccine Efficacy: A Randomised, Controlled Trial Comparing the Typhoid Vaccines M01ZH09 with Placebo and Ty21a. PLoS Neglected Tropical Diseases. 2016 August 17;10(8):e0004926.
Green CA, Scarselli E, Sande CJ, Thompson AJ, de Lara CM, Taylor KDS, Haworth K, Del Sorbo M, Angus B, Siani L, Di Marco S, Traboni C, Folgori A, Colloca S, Capone S, Vitelli A, Cortese R, Klenerman P, Nicosia A, Pollard AJ. Chimpanzee adenovirus-and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults. Science Translational Medicine. 2015 Aug 12;7(300):300ra126.
Marsay L*, Dold C*, Green CA*, Rollier CS, Norheim G, Sadarangani M, Shanyinde M, Brehony C, Thompson AJ, Sanders H, Chan H, Haworth K, Derrick JP, Feavers IM, Maiden MC, Pollard AJ (*shared first author position). A novel meningococcal outer membrane vesicle vaccine with constitutive expression of FetA: A phase I clinical trial. Journal of Infection. 2015 Sep;71(3):326-37
Green CA, Scarselli E, Voysey M, Capone S, Vitelli A, Nicosia A, Cortese R, Thompson AJ, Sande CS, de Lara C, Klenerman P, Pollard AJ. Safety and Immunogenicity of novel respiritaory synctial virus (RSV) vaccines based on the RSV viral proteins F, N and M2-1 encoded by simian adenovirus (PanAd3-RSV) and MVA (MVA-RSV); protocol for an open label, dose-escalation, single-centre, phase 1 clinical trial in healthy adults. BMJ Open. 2015 Oct 28;5(10):e008748
View all publications in research portal